Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

What Was Tested

This registered phase 3 trial tested Liraglutide.

It had two arms (groups): Placebo (placebo comparator) and Intervention (active comparator).

The registry classes the interventions as drug.

Who Took Part

36 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age \>18 years. Body mass index \>27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of polycystic ovary syndrome.

The full record lists 3 inclusion and 6 exclusion criteria; among the exclusions: diagnosis of diabetes mellitus or treatment with anti-glycemic drug; pancreatitis (acute or chronic) in the past; active malignancy.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2014-01 with completion listed for 2015-01.

It ran at 1 site in Israel.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Glucose levels 2 hours after 75 gr OGTT (time frame: 6 weeks).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Liraglutide in 36 people.

Its size is small, so on its own it can only give an early look.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, all human trials.